Therapy for Rare Cancers receives FDA approval following trials at Penn's Abramson Cancer

(University of Pennsylvania School of Medicine) The US Food and Drug Administration (FDA) has approved the first ever non-surgical treatment for the rare neuroendocrine cancers pheochromocytoma and paraganglioma. The approval was based on a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania and was granted to Progenics Pharmaceuticals for AZEDRA (iobenguane I131).
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news